Vigil Neuro
Liyue Huang is a seasoned professional in drug metabolism and pharmacokinetics (DMPK) with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as Sr. Director of DMPK at Vigil Neuroscience since June 2022, Liyue previously held the position of Director of DMPK at Foghorn Therapeutics, Inc. from September 2019 to June 2022. Liyue has also worked as Associate Director at Epizyme, Principal Scientist, and Senior Scientist at Amgen, as well as a Scientist at AstraZeneca. Liyue began a career in research as a Postdoc at GSK. Academic qualifications include a Ph.D. in Toxicology from the University of Kentucky and a Bachelor's degree in Medicine from Zhejiang University.
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.